tradingkey.logo

Grail Inc

GRAL
查看详细走势图
100.070USD
+6.010+6.39%
收盘 02/06, 16:00美东报价延迟15分钟
3.62B总市值
亏损市盈率 TTM

Grail Inc

100.070
+6.010+6.39%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+6.39%

5天

+2.30%

1月

-3.76%

6月

+202.51%

今年开始到现在

+16.92%

1年

+203.33%

查看详细走势图

TradingKey Grail Inc股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Grail Inc当前公司基本面数据相对健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名86/392位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价105.00。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Grail Inc评分

相关信息

行业排名
86 / 392
全市场排名
212 / 4521
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
中性

Grail Inc亮点

亮点风险
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
业绩高增长
公司营业收入稳步增长,连续3年增长126.09%
估值低估
公司最新PE估值-9.39,处于3年历史低位
机构减仓
最新机构持股25.81M股,环比减少20.00%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值1.72K

分析师目标

根据 4 位分析师
买入
评级
105.000
目标均价
+11.63%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Grail Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Grail Inc简介

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
公司代码GRAL
公司Grail Inc
CEORagusa (Robert)
网址https://grail.com/
KeyAI